BMB-201 is a serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor agonist described as a non-hallucinogenic psychoplastogen which is under development for the treatment of depression, anxiety, pain, and other indications. Its route of administration is unspecified.
BMB-201 is a prodrug of another compound known as BMB-A39a. It acts as a biased partial agonist of the serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors. BMB-A39a is less efficacious in activating G<sub>q</sub> signaling at the serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors compared to psilocin ( = 68% vs. 82% at 5-HT<sub>2A</sub> and 79% vs. 95% at 5-HT<sub>2C</sub> for BMB-201 and psilocin, respectively). The value of BMB-A39a in activating the serotonin 5-HT<sub>2C</sub> receptor is around 10-fold higher than for activating the 5-HT<sub>2A</sub> receptor ( = 6.7nM and 71.2nM, respectively).
In addition to the serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors, BMB-A39a is a potent partial agonist of the serotonin 5-HT<sub>1F</sub> and 5-HT<sub>6</sub> receptors. It shows minimal or negligible activity in activating the serotonin 5-HT<sub>2B</sub> receptor ( < 20%) and does not activate other serotonin receptors.
BMB-201 is said to have minimal or absent psychedelic effects due to its reduced serotonin 5-HT<sub>2A</sub> receptor intrinsic activity but to potently induce neuroplasticity. It has been reported to show effectiveness in animal models of depression, anxiety, pain, and substance use disorder.
The exact chemical structure of BMB-201 does not yet appear to have been disclosed. However, it is known to be a tryptamine derivative. In addition, Bright Mind Biosciences has patented tryptamines and prodrugs as serotonin 5-HT<sub>2</sub> receptor modulators.
BMB-201 is under development by Bright Minds Biosciences. As of September 2025, it is in the preclinical research stage of development for the treatment of depressive disorders and pain.